Biointron Insights: Antibody Industry Trends (Q3 2026 Insights, Trends & Analysis)

Biointron’s Q3 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September. This quarter, ten novel antibody-based drugs have received first global approval.

1. Recibokibart (华亦净)

2. Felzartamab (境斐)

3. Garetosmab (Pasatru)

4. Anflekitug (Yisaina)

5. Velinotamig (维可妥)

6. Lecankitug (丽倍坦)

7. Clulevibart (Inmular)

8. Retavibart (新多妥/Xinduotuo)

9. Apitegromab (Isembyld)

10. Gefurulimab (Klygefa)

Q3 2026 saw several licensing and acquisition agreements around a variety of antibody targets for up to USD$2.9 billion, although there was less deal activity than the previous quarter.

Antibody discovery with AI has become a large topic in research, as well as antibody technologies such as mRNA-encoded antibodies. A particular antibody to watch in Q4 2026, with a soon-approaching approval action date, is imsidolimab for generalized pustular psoriasis.

Gain exclusive insights into current trends such as:

• 📣 10 novel antibody drugs approved for the first time in Q3 2026

• 💸 Top 20 antibody drug deals, including M&As, licensing agreements, and collaborations of up to US$2.9B

• 🤖 Artificial intelligence (AI)-driven drug discovery is moving toward experimental validation

• 🔬 mRNA-encoded antibodies allow the body's cellular machinery to transiently produce and secrete antibodies

• 💊 A list of antibody drugs with soon-approaching approval action dates to keep an eye out for in Q4 2026

Please fill in the form below to download